ClinicalTrials.gg
Not yet recruitingNCT07680179Updated Sep 29, 2026

Peer Delivered Youth Suicide Prevention in Nepal

An interventional study of Enhanced Usual Care (EUC) and Youth-focused, Peer-delivered, Family-engaged Suicide Prevention Package (YPF-SuPP) in Suicide and Suicide Prevention, sponsored by Yale University. Not yet recruiting at 1 site in Nepal. Open to participants aged 12 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionSuicide PreventionRegistry: SuicideReclassifiedWhy we changed it
Registry
Suicide — the first condition term the registry derived for this study.
ClinicalTrials.gg
Suicide Prevention
Why
  1. Suicide is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Suicide Prevention, a narrower term within Suicide.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Yale University · Not applicable, Interventional, and Prevention

Updated Sep 29, 2026Start date movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
12 Years to 24 Years
Sex
All
01

Study summary

South Asia has the highest suicide rate in the world with important risk profile differences from high-income settings. Investigators will conduct formative research to co-design a package of brief interventions and implementation strategies to prevent youth-suicide and then test the package in a pilot feasibility hybrid type 2 cluster randomized controlled trial in Nepal. Potential health impacts may be substantial as results can be applied not only in similar South Asian primary healthcare contexts, but also in low-resource settings in the US and abroad, where the suicide burden remains high.

Using experience-based co-design and equity-focused implementation frameworks, this study will assess the feasibility and acceptability of a Youth-focused, Peer-delivered, Family-engaged Suicide Prevention Package (YPF-SuPP) integrated within existing mhGAP services in Nepal's decentralized primary healthcare system. This pilot trial will generate preliminary data to inform the design of a future fully powered effectiveness trial and potential scale-up of youth suicide prevention strategies.

Read the detailed description

Following participatory youth and family-anchored codesign, this study aims to conduct a pilot hybrid type 2 randomized controlled trial to assess the feasibility, acceptability, and fidelity of YPF-SuPP implementation. YPF-SuPP builds on existing mhGAP suicide prevention activities and includes peer-supported brief interventions for at-risk youth and their families, emphasizing family-engaged safety planning (including a novel indigenous jewelry-based approach) and structured contact follow-up. This hybrid type 2 mixed-methods pilot study is designed to assess clinical and implementation outcomes and to inform the design of a future effectiveness trial. This registration focuses on the pilot randomized controlled trial component.

The study will use a pilot cluster randomized controlled trial design in Manahari Municipality, which includes two Primary Health Centers (PHCs), each serving a catchment area of approximately 5,000 youth. PHC catchment areas will serve as clusters and will be randomly assigned to either YPF-SuPP plus Enhanced Usual Care (EUC) or EUC alone. EUC consists of care from mhGAP-trained primary care providers and Community Counselors. Blinding of participants and assessors is not feasible; however, the statistical analysis team will be blinded.

This study is a pilot feasibility cluster randomized controlled trial. Youth at risk for suicide will be enrolled, with half assigned to the intervention arm and half to the control arm. Randomization will occur at the primary health care facility level.

02

Conditions studied

  • Suicide
  • Suicide Prevention

Browse trials for

03

In context

Suicide Prevention Reclassified

186 studies on the registry are indexed under Suicide Prevention; 92 are open to participants now.

This study's planned enrollment of 160 is above the median of 140 across 167 interventional studies indexed under Suicide Prevention.

Browse Suicide Prevention studies →

Lead sponsor

Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Compared within Suicide Prevention, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Suicide. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
12 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Peer Volunteers

  • Age ≥18 years
  • No current untreated mental disorder or suicide risk, as assessed and confirmed by a Nepali mental health specialist (MD or PhD)
  • Meets hiring and eligibility criteria of the local implementing partner NGO
  • Fluent in spoken Nepali

Trial Youth Patient Participants

  • Age 12-24 years
  • Resident of the study site
  • Screens positive to the Nepali Ask Suicide Screening Questions or a lifetime history of a suicide attempt
  • Ability to provide or assent
  • For participants under 18 years of age, written informed consent from a legal guardian
  • Fluent in Nepali

Family Members (intervention group only)

  • Family member (defined as any individual that is a parent, grandparent, aunt/uncle, or cousin as well as significant others) selected by the youth participants enrolled in the study
  • Resident of the study site
  • Over 18 years of age
  • Ability to provide informed consent or assent
  • Fluent in Nepali

Exclusion criteria

Exclusion Criteria:

Peer Volunteers

  • Plans to leave the peer volunteer role within the next 6 months
  • Unable to provide voluntary for any reason

Trial Youth Patient Participants

  • Requires immediate psychiatric hospitalization at the time of assessment
  • Unable to provide informed consent or assent due to impaired decision-making capacity
  • Participants under 18 years of age without written informed consent from a legal guardian
  • Planning to leave the study area in the next 6 months

Family Members

  • Requires immediate psychiatric hospitalization at the time of assessment
  • Unable to provide informed consent or assent due to impaired decision-making capacity
  • Planning to leave the study area in the next 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Enhanced Usual Care (EUC)

    Participants will receive standard government mental health services provided by mhGAP-trained clinicians and a referral to a Community Counselor for psychosocial counseling. mhGAP training is based on the World Health Organization (WHO) mental health Gap Action Programme (mhGAP) Intervention Guide version 2.0. Clinicians are trained to detect and treat all common mental health conditions. Following training, prescribers participate in regular supervision sessions with a psychiatrist. Community Counselors hold a government approved certificate in counseling and receive supportive supervision from a Nepali psychologist. Youth participants in this arm will receive care according to mhGAP treatment protocols. Participants requiring additional care may be referred to a psychiatrist at a local specialty service and will remain in the assigned study arm following referral.

    Behavioral: Enhanced Usual Care (EUC)

  • Experimental
    EUC + YPF-SuPP

    Participants in this arm will receive EUC plus the Youth-focused, Peer-delivered, Family-engaged Suicide Prevention Package (YPF-SuPP). Participants are matched with a trained Peer who will deliver 12 sessions over 6-months. Peers are supervised by Nepali clinicians. Peers co-design an individualized culturally adapted Aashako Kiran (Ray of Hope) Safety Plan through indigenous jewelry and a bespoke book. Participants will also identify a trusted adult who will receive three psychoeducational sessions focused on recognizing emotional distress and suicide risk, supporting implementation of the safety plan, strengthening communication, and facilitating help-seeking. Peers provide structured contact follow-up including emotional support, problem-solving, and fun activities to target self-efficacy, belonging, and social connections.

    Behavioral: Enhanced Usual Care (EUC) · Behavioral: Youth-focused, Peer-delivered, Family-engaged Suicide Prevention Package (YPF-SuPP)

Interventions

  • BehavioralEnhanced Usual Care (EUC)

    Standard government mental health services provided by mhGAP-trained clinicians.

  • BehavioralYouth-focused, Peer-delivered, Family-engaged Suicide Prevention Package (YPF-SuPP)

    YPF-SuPP consists of two evidence-based components delivered by a trained and supervised Peer: (1) a Nepali-adapted "aashako kiran" ("ray of hope and light") safety planning intervention, which provides psychosocial support and identifies coping and help-seeking strategies and problem solving for challenges. It also includes the selection of a "safe" family member and provides culturally anchored family engagement to address escalating distress, social support, uptake of local suicide-specific prevention resources, and environmental safety strategies; (2) peer-delivered contact follow-up, consisting of up to 12 Peer led sessions with the youth over six months, conducted under supervision of a mental health clinician to enhance hopefulness, connectedness, and confidence accessing personalized help-seeking.

06

What researchers measure

Primary outcomes

  1. Adoption of YPF-SuPP by Peers (Training Attendance)

    Percentage of invited peer volunteers that completing training.

    Time frame: Baseline

  2. Feasibility and Acceptability of YPF-SuPP by Peers

    The total number of Peers continuing to provide services at 6 months divided by total number of Peers that initiated training.

    Time frame: 6 months

  3. Peer Competency using ENhancing Assessment of Common Therapeutic (ENACT)

    Competency will be assessed using the ENACT 18-item checklist during standardized behavioral rehearsals. Competency defined as ≥75% of items correctly demonstrated. Score ranging from 0 (not done/poor) to 3 (consistently/well done).

    Time frame: Baseline, 6 months

  4. Adoption of Youth at Risk

    Number of participants that remain in the intervention at 6 months; target ≥65%.

    Time frame: 6 months

  5. Adoption of Family Members

    Number of participants that complete all follow up assessments; target ≥65%.

    Time frame: 6 months

  6. Mean score Peer Suicide Prevention Knowledge

    Assessed using a 9-item mhGAP-based knowledge survey covering suicide risk, management, and caregiver engagement. Fidelity defined as ≥75% correct responses. Youth at risk will also complete a self-report fidelity checklist. Score ranging from 0-9 with higher scores indicating greater knowledge.

    Time frame: Baseline, 6 months

  7. Missing Data

    Percentage of missing data

    Time frame: Baseline, 6 months

  8. Mean score Youth Suicide-Related Coping Skills

    A 17-item self-report instrument evaluating coping strategies used to manage suicidal thoughts and emotional distress. Total score ranging from 17 to 85 with higher scores indicating better coping skills.

    Time frame: Baseline, 3 months, 6 months

Secondary outcomes

  1. Family suicide prevention self-efficacy

    Family self-efficacy will be assessed using the 9-item Parent Suicide Prevention Self-Efficacy Scale (Czyz et al., 2018) - modified for other family members in collaboration with the measure developer. Items are rated 0 (not confident at all) to 10 (completely confident) scale to understand parent's engagement in managing their family member's suicidal crisis. Family will be defined as the participant defines their family, which can include romantic partners as well as close friends.

    Time frame: Baseline, 6 months

  2. Mean score Beck Scale for Suicide Ideation (BSSI)

    A 19-item self-report instrument. Items scored 0-2 and summed (range 0-36), with higher scores indicating greater severity.

    Time frame: Baseline, 3 months, 6 months

07

Study locations

1 site
  • Sochai Nepal
    Makwanpur, Nepal
    • Archana Shrestha, PhD · Contact977-980-1002245
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2028, 20 months later.

Of 127 non-industry interventional studies with no phase under Suicide Prevention, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 20 months is below that.

Counting every sponsor, half of 129 studies reached it within 28 months; a quarter within 12 and three quarters within 53.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 2, 2026
StartEst.
Oct 2026was Sep 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Oct 2026
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Sep 2026→Oct 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07680179
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Ashley K Hagaman, PhD, MPH
Contact
ashley.hagaman@yale.edu
203-785-7651
Ashley K Hagaman, PhD, MPH
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion